Showing results (1091-1100 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|January 9, 2025
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)Stanley Szefler, Jonathan Corren, Jonathan I Silverberg, et al.Immunotherapy|April 4, 2025
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitorsXiao Hu, Angie Mae Rodday, Anastasia Gurinovich, et al.Immunotherapy|November 18, 2024
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in ChinaXinyi Xu, Linyu Geng, Xue Xu, et al.Immunotherapy|October 11, 2024
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinomaOmar Elghawy, Adam Barsouk, Reema Patel, et al.Immunotherapy|September 26, 2024
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokineticsIftekhar Mahmood, Zhaoyang LiImmunotherapy|September 11, 2024
Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature reviewZiwei Chen, Jingrui Zhou, Weimin Chen, et al.Immunotherapy|September 11, 2024
Cost-effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancerRuizhe Liu, Yijia Zhao, Fenghao Shi, et al.Immunotherapy|March 4, 2025
Immunotherapies for prevention and treatment of type 1 diabetesRebecca JeunImmunotherapy|February 25, 2025
Immunotherapy rechallenge after significant toxicity - can it be done successfully?Ashley Tan, Tara McSweeney, Nisha Sikotra, et al.Immunotherapy|February 17, 2025
Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myelomaSophie Carlson, Tasha L Lin, Sarah M LarsonPageof 190